In colon cancer, PRDM1 suppressed tumorigenesis via inhibition of TP53, MYC, and insulin-like growth factor-binding protein 3 (IGFBP3) [25,27,33], while in non-GI cancers, PRDM1 impeded the development of glioma [32], lung cancer [30], and melanoma [26]. Here, IGFBP3 is linked to malignant colon neoplasm.